The USFDA has approved tebentafusp-tebn, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for HLA-A*02:01-positive adult patients suffering from unresectable or metastatic uveal melanoma. Clinical trial details Safety information Most common adverse reactions: Cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting.
Most common laboratory abnormalities Recommended dosages (IV route) Day 1: 20 mcg, Day 8: 30 mcg, Day 15: 68 mcg, and 68 mcg once weekly thereafter Conclusion Uveal melanoma, although rare, is associated with a moderately high mortality rate and mostly tends to metastasize. Tebentafusp-tebn showed promising outcomes in terms of mean overall survival and progression-free survival in HLA-A*02:01-positive adult patients suffering from unresectable or metastatic uveal melanoma.…
